NextBioMedical Signs Distribution Agreement with Terumo Europe for Nexpier-F

NextBioMedical has signed a distribution agreement with Terumo Europe for 'Nexpier-F' in selected countries within the Europe, Middle East, and Africa (EMEA) region.

According to NextBioMedical on June 1, under this agreement, Terumo will be exclusively responsible for the sales and distribution of Nexpier-F in certain countries of the EMEA region. Both companies plan to gradually expand the scope of their partnership to additional territories, based on market performance and the success of their collaboration.

Terumo, a global medical device company founded in Tokyo, Japan in 1921, operates in over 160 countries and regions worldwide. The company provides a wide range of medical solutions focused on therapeutic procedures, hospital operations, and life sciences, and is recognized as a leader in the global medical device industry.

Nexpier-F, developed by NextBioMedical, is an intravascular embolization device used for vascular embolization. It has obtained certifications from Korea KMFDS, Europe CE-MDD, and Canada, and is currently being used in actual clinical settings. The company is also smoothly conducting clinical trials for U.S. FDA approval and is continuously participating in major global conferences to expand product awareness and its professional network.

A NextBioMedical representative stated, "We have steadily accumulated meaningful clinical data based on CE certification," adding, "Collaboration with a global medical device company like Terumo is a very significant step forward in our market expansion strategy."

This content was produced with the assistance of AI translation services.